EGFR and non-small cell lung carcinoma: Consequently, these results demonstrated that except for erlotinib-sensitive PC9 cells, FGFC1 could selectively inhibit the growth of erlotinib-resistant H1975 NSCLC cells, which harbors L858R/T790M double mutation of EGFR. Due to T790M might be the most important mutation, leading to the development of TKI resistance (Rajappa et al., 2019), next we mainly evaluated the effects of FGFC1 on EGFRT790M mutant NSCLC cells.